Biogen thought it had developed a treatment for Lou Gehrig’s disease, a devastating illness that leaves patients trapped in their own atrophying bodies until, inevitably, they die. After early clinical studies yielded encouraging results a few years ago, the biotech company took a home-run swing and launched a huge final-stage trial to prove the drug worked.
